A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers
Latest Information Update: 14 Dec 2024
At a glance
- Drugs Cisplatin/vinblastine (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Chondrosarcoma; Chordoma; Colon cancer; Colorectal cancer; Head and neck cancer; Leiomyosarcoma; Liposarcoma; Liver cancer; Lung cancer; Lymphoma; Malignant melanoma; Pancreatic cancer; Sarcoma; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions
- Acronyms INTENSITY-IT-01; IT-01; KEYNOTE A10
- Sponsors Intensity Therapeutics
Most Recent Events
- 18 Nov 2024 According to an Intensity Therapeutics media release, company presented final safety and efficacy data from this trial during an oral podium presentation in a late-breaking session at the 2024 Connective Tissue Oncology Society ("CTOS") on November 16, 2024, at 9 AM PST.
- 18 Nov 2024 Results published in an Intensity Therapeutics Media Release.
- 02 Nov 2023 Results published in an Intensity Therapeutics Media Release.